Genetic screening for reproductive planning
Methodological and conceptual issues in policy analysis
Dados Bibliográficos
| ID | 11023739 |
|---|---|
| Autores | David A Asch (0000-0002-7970-286X, Philadelphia VA Medical Center), J C Hershey, Mark V Pauly (0000-0003-4957-4825), James Patton, J P Patton, M Kathryn Jedrziewski, Michael T Mennuti |
| Ano | 1996 |
| Volume | 86 |
| Fascículo | 5 |
| Páginas | 684-690 |
| Data de publicação | 1996-05-01 |
| Open Access | Não |
| Tipo | ARTICLE |
| Periódico | American Journal of Public Health (JOURNAL) |
| Identificadores do periódico | ISSN: 0090-0036 • E-ISSN: 1541-0048 |
| Editora | American Public Health Association (PUBLISHER • US) |
| DOI | 10.2105/ajph.86.5.684 |
| PMID | 8629720 |
| OpenAlex | W2065892975 |
| Idioma | EN |
| Citações recebidas | 2 |
| Referências citadas | 20 |
OBJECTIVES: This paper explores several critical assumptions and methodological issues arising in cost-effectiveness analyses of genetic screening strategies in the reproductive setting. METHODS: Seven issues that arose in the development of a decision analysis of alternative strategies for cystic fibrosis carrier screening are discussed. Each of these issues required a choice in technique. RESULTS: The presentations of these analyses frequently mask underlying assumptions and methodological choices. Often there is no best choice. In the case of genetic screening in the reproductive setting, these underlying issues often touch on deeply felt human values. CONCLUSIONS: Space limitations for published papers often preclude explaining such choices in detail; yet these decisions determine the way the results should be interpreted. Those who develop these analyses need to make sure that the implications of important assumptions are understood by the clinicians who will use them. At the same time, clinicians need to enhance their understanding of what these models truly mean and how they address underlying clinical, ethical, and economic issues
Economics · Engineering ethics · Management science · Risk analysis (engineering) · Cystic Fibrosis Research Advances · Health Systems, Economic Evaluations, Quality of Life · Medicine · Prenatal Screening and Diagnostics · Psychology
| Citações por ano | 0,07 |
|---|---|
| Intervalo de citações | 1999 - 2006 (8) |
| Altamente citado | Não |